Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes

Fig. 3

a Salbutamol urine concentration (ng.mL−1) before (dark grey columns) and after correction (light grey columns) for urine density during the rest pharmacokinetic session. Bivariate comparisons (Wilcoxon sign rank test) between corrected and uncorrected time-stratified values. Bonferroni correction of the significance level: * p < 0.01. b Salbutamol urine concentration (ng.mL−1) before (dark grey columns) and after correction (light grey columns) for urine density during the exercise pharmacokinetic session. Bivariate comparisons Wilcoxon (sign rank test) between corrected and uncorrected time-stratified values. Bonferroni correction of the significance level: *p < 0.01

Back to article page